Q1 EPS Estimates for Globus Medical Raised by Zacks Research

Key Points

• Zacks Research raised its Q1 2026 EPS estimate for Globus Medical to $0.90 (from $0.89) and maintains a Strong-Buy rating, while projecting FY2027 EPS of $4.70 and FY2028 EPS of $5.27.
• Globus recently beat quarterly expectations, reporting $1.28 EPS versus $1.06 expected and revenue of $826.4M versus $803.3M, a 25.7% year-over-year revenue increase with an 18.3% net margin.
• Analyst sentiment is broadly positive—MarketBeat shows an average rating of "Moderate Buy" with an average target of $104.36, and several firms (e.g., Piper Sandler, Barclays) have raised price targets this year.

Globus Medical, Inc. (NYSE:GMED - Free Report) - Zacks Research lifted their Q1 2026 EPS estimates for Globus Medical in a research note issued to investors on Thursday, April 23rd. Zacks Research analyst Team now forecasts that the medical device company will post earnings per share of $0.90 for the quarter, up from their prior forecast of $0.89. Zacks Research currently has a "Strong-Buy" rating on the stock. The consensus estimate for Globus Medical's current full-year earnings is $4.46 per share. Zacks Research also issued estimates for Globus Medical's Q1 2027 earnings at $1.09 EPS, Q4 2027 earnings at $1.25 EPS, FY2027 earnings at $4.70 EPS, Q1 2028 earnings at $1.22 EPS and FY2028 earnings at $5.27 EPS.

GMED has been the subject of several other research reports. Piper Sandler reissued an "overweight" rating and issued a $115.00 price objective (up from $90.00) on shares of Globus Medical in a research note on Thursday, January 8th. Citigroup reissued a "market perform" rating on shares of Globus Medical in a research note on Thursday, January 8th. Barclays raised their price objective on shares of Globus Medical from $118.00 to $123.00 and gave the company an "overweight" rating in a research note on Wednesday, February 25th. BTIG Research reissued a "neutral" rating on shares of Globus Medical in a research note on Tuesday, December 30th. Finally, Canaccord Genuity Group raised their price objective on shares of Globus Medical from $105.00 to $112.00 and gave the company a "buy" rating in a research note on Friday, January 9th. Three investment analysts have rated the stock with a Strong Buy rating, eight have issued a Buy rating and five have issued a Hold rating to the company's stock. According to MarketBeat.com, Globus Medical has an average rating of "Moderate Buy" and an average target price of $104.36.

Globus Medical Price Performance

Shares of GMED opened at $94.49 on Friday. Globus Medical has a 1-year low of $51.79 and a 1-year high of $101.40. The stock has a market cap of $12.78 billion, a PE ratio of 23.98, a P/E/G ratio of 2.22 and a beta of 1.09. The firm has a 50-day simple moving average of $89.86 and a two-hundred day simple moving average of $84.52.

Globus Medical (NYSE:GMED - Get Free Report) last announced its quarterly earnings results on Tuesday, February 24th. The medical device company reported $1.28 earnings per share for the quarter, beating analysts' consensus estimates of $1.06 by $0.22. Globus Medical had a net margin of 18.30% and a return on equity of 12.57%. The business had revenue of $826.42 million during the quarter, compared to analysts' expectations of $803.29 million. During the same period last year, the business earned $0.84 earnings per share. The business's revenue for the quarter was up 25.7% on a year-over-year basis.

Insider Transactions at Globus Medical

In related news, EVP Kelly Huller sold 20,000 shares of Globus Medical stock in a transaction that occurred on Wednesday, February 25th. The shares were sold at an average price of $94.50, for a total value of $1,890,000.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. 18.51% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

A number of institutional investors have recently added to or reduced their stakes in the company. SMART Wealth LLC purchased a new position in Globus Medical in the first quarter worth approximately $273,000. Inspire Investing LLC lifted its stake in Globus Medical by 234,962.5% in the first quarter. Inspire Investing LLC now owns 18,805 shares of the medical device company's stock worth $1,620,000 after acquiring an additional 18,797 shares during the last quarter. Janney Montgomery Scott LLC lifted its stake in Globus Medical by 23.1% in the first quarter. Janney Montgomery Scott LLC now owns 26,736 shares of the medical device company's stock worth $2,304,000 after acquiring an additional 5,022 shares during the last quarter. Fort Washington Investment Advisors Inc. OH lifted its stake in Globus Medical by 11.6% in the first quarter. Fort Washington Investment Advisors Inc. OH now owns 356,811 shares of the medical device company's stock worth $30,743,000 after acquiring an additional 37,220 shares during the last quarter. Finally, Aaron Wealth Advisors LLC purchased a new position in Globus Medical in the first quarter worth approximately $405,000. Hedge funds and other institutional investors own 95.16% of the company's stock.

Globus Medical Company Profile

Globus Medical, Inc NYSE: GMED is a leading medical device company specializing in musculoskeletal solutions for spine and orthopaedic applications. Founded in 2003 by David C. Paul and headquartered in Audubon, Pennsylvania, the company develops, manufactures and markets implantable devices and surgical instruments designed to treat spinal disorders and promote bone healing. Its product portfolio encompasses solutions for minimally invasive and open surgical procedures, including interbody fusion devices, pedicle screw systems, and biologics used to enhance fusion outcomes.

In addition to its core spine business, Globus Medical has expanded into robotics and navigation systems to support precision and efficiency in the operating room.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.